Cargando…

The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study

INTRODUCTION: Isoniazid-resistant, rifampin susceptible tuberculosis (INHR-TB) is the most common form of drug resistant TB globally. Treatment of INHR-TB with standard first-line therapy is associated with high rates of multidrug resistant TB (MDR-TB). We modelled the potential impact of INHR-TB de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romanowski, Kamila, Campbell, Jonathon R., Oxlade, Olivia, Fregonese, Federica, Menzies, Dick, Johnston, James C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345486/ https://www.ncbi.nlm.nih.gov/pubmed/30677101 http://dx.doi.org/10.1371/journal.pone.0211355

Ejemplares similares

Tuberculosis preventive treatment in people living with HIV—Is the glass half empty or half full?
por: Oxlade, Olivia, et al.
Publicado: (2021)

Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada
por: Romanowski, Kamila, et al.
Publicado: (2017)

Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis
por: Uppal, Aashna, et al.
Publicado: (2021)

The latent tuberculosis cascade-of-care among people living with HIV: A systematic review and meta-analysis
por: Bastos, Mayara Lisboa, et al.
Publicado: (2021)

Effects of programmatic interventions to improve the management of latent tuberculosis: a follow up study up to five months after implementation
por: Yanes-Lane, Mercedes, et al.
Publicado: (2021)

Treatment of drug-resistant tuberculosis
por: Pinto, Lancelot, et al.
Publicado: (2011)

Solutions to improve the latent tuberculosis Cascade of Care in Ghana: a longitudinal impact assessment
por: Barss, Leila, et al.
Publicado: (2020)

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2019)

Genotypic and phenotypic drug-resistance detection and prevalence of heteroresistance in patients with isoniazid- and multidrug-resistant tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

Scaling up investigation and treatment of household contacts of tuberculosis patients in Brazil: a cost-effectiveness and budget impact analysis
por: Bastos, Mayara Lisboa, et al.
Publicado: (2022)

Modeling the impact of tuberculosis interventions on epidemiologic outcomes and health system costs
por: Oxlade, Olivia, et al.
Publicado: (2015)

Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis
por: Yanes-Lane, Mercedes, et al.
Publicado: (2021)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
por: Jhun, Byung Woo, et al.
Publicado: (2020)

A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis
por: Fox, Gregory J., et al.
Publicado: (2013)

Isoniazid-Resistant Tuberculosis, Taiwan, 2000–2010
por: Lai, Chih-Cheng, et al.
Publicado: (2011)

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis
por: Balcells, Maria Elvira, et al.
Publicado: (2006)

Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study
por: Tseng, Chia-Lin, et al.
Publicado: (2011)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis
por: Menzies, Dick, et al.
Publicado: (2009)

Detecting Novel Genetic Variants Associated with Isoniazid-Resistant Mycobacterium tuberculosis
por: Shekar, Sandhya, et al.
Publicado: (2014)

Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti
por: Jacquet, Vary, et al.
Publicado: (2006)

Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas
por: Pienaar, Elsje, et al.
Publicado: (2018)

Enhancing the public health impact of latent tuberculosis infection diagnosis and treatment (ACT4): protocol for a cluster randomised trial
por: Oxlade, Olivia, et al.
Publicado: (2019)

Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates
por: Zhang, Zhe, et al.
Publicado: (2015)

In vitro Evaluation of Isoniazid Derivatives as Potential Agents Against Drug-Resistant Tuberculosis
por: Marquês, Joaquim Trigo, et al.
Publicado: (2022)

Time to Culture Conversion of Bedaquiline and High-Dose Isoniazid for Drug-Resistant Tuberculosis
por: Walsh, Kathleen F, et al.
Publicado: (2022)

Diagnostic performance of DNA microarray for detecting rifampicin and isoniazid resistance in Mycobacterium tuberculosis
por: Sun, Bingqi, et al.
Publicado: (2021)

Do We Need to Detect Isoniazid Resistance in Addition to Rifampicin Resistance in Diagnostic Tests for Tuberculosis?
por: Denkinger, Claudia M., et al.
Publicado: (2014)

Pre-Existing Isoniazid Resistance, but Not the Genotype of Mycobacterium Tuberculosis Drives Rifampicin Resistance Codon Preference in Vitro
por: Bergval, Indra, et al.
Publicado: (2012)

Detection of KatG/inhA Mutation to Guide Isoniazid and Ethionamide Use for Drug-resistant Tuberculosis
por: Namburete, Evangelina
Publicado: (2017)

Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates
por: Muthaiah, Muthuraj, et al.
Publicado: (2017)

Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010–2016
por: Campbell, Jonathon R., et al.
Publicado: (2022)

Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2020)

Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
por: Somoskovi, Akos, et al.
Publicado: (2001)

Impact of Bacterial Genetics on the Transmission of Isoniazid-Resistant Mycobacterium tuberculosis
por: Gagneux, Sebastien, et al.
Publicado: (2006)

Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009
por: Jenkins, Helen E., et al.
Publicado: (2011)

Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis
por: Machado, Diana, et al.
Publicado: (2012)

Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis
por: Lee, Jong-Hee, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0pasec0sb0q6gl0hmiq0n7l7hs